ArticlePloS one2026
Bladder cancer-induced CVD mortality: Role of CAPG protein.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveExplore the causes and mechanisms of bladder cancer-induced Cardiovascular diseases (CVD) death.
methodWe acquired bladder cancer patient data from the SEER database to evaluate CVD death risk. Cross-WGCNA was employed to identify comorbidity genes linking bladder cancer and heart failure. Functional phenotypes of bladder cancer cell lines were analyzed using cell culture, transaction, CCK-8, and Transwell assays, while ELISA determined extracellular target protein concentrations. Myocardial cell function was assessed by examining cell proliferation, collagen I levels, and mitochondrial membrane potential.
resultOur study, analyzing 140,760 bladder cancer patients from the SEER database, revealed that CVD is a major cause of death, increasing risk by 18%. Cross-WGCNA and Lasso regression identified SFRP1 and CAPG as key serum proteins linked to bladder cancer and heart failure. Regulating these proteins' mRNA levels significantly impacts cancer proliferation, migration, and invasion. CAPG, in particular, suppresses myocardial cell function. We discovered SB525334 as a strong CAPG inhibitor in bladder cancer cells, potentially enhancing cisplatin's effectiveness by targeting CAPG.
conclusionBladder cancer patients face an elevated CVD death risk due to high CAPG protein expression, which can raise serum CAPG levels and harm cardiomyocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.